Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Compensation fund

- PMLiVE

Moderna shares positive late-stage results for COVID-19/flu combination vaccine

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

WHA announces progress of WHO Member States to conclude pandemic agreement

The agreement is aimed at preventing a repeat of the global health, economic and social impacts of the COVID-19 pandemic

- PMLiVE

WHO updates drug-resistant bacteria list to develop new treatments for AMR

The 2024 BPPL list includes 15 families of antibiotic-resistant bacteria

- PMLiVE

Governments continue proposed pandemic agreement progress ahead of World Health Assembly

The meeting focusing on ‘All for Health, Health for All’ takes place on 27 May to 7 June 2024

- PMLiVE

Takeda’s Qdenga becomes second dengue vaccine to receive WHO prequalification

Approximately half of the global population is at risk of mosquito-borne viral disease

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

WHO opens application period for 2025 Model Lists of Essential Medicines

The deadline to submit ahead of the 25th WHO Expert Committee meeting is 1 November 2024

- PMLiVE

Study reveals third COVID-19 vaccine dose improves defence in vulnerable patients

Approximately 90% of patients who received a third dose developed significant levels of antibodies

- PMLiVE

Sanofi and Novavax announce COVID-19 vaccine licensing agreement worth over $1.2bn

The deal gives Sanofi a licence to use Novavax’s COVID-19 vaccine in combination with its own flu vaccines

- PMLiVE

Researchers’ new vaccine technology shows efficacy against broad range of coronaviruses

The vaccine provided protection against coronaviruses that have not yet emerged

- PMLiVE

AstraZeneca begins global withdrawal of COVID-19 vaccine following decline in demand

The company applied to voluntarily withdraw its European marketing authorisation on 5 March

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links